术后神经认知障碍与延迟神经认知恢复预防效果模式:随机试验的系统综述与元回归
该研究通过系统检索Ovid MEDLINE、EMBASE、Web of Science和ClinicalTrials.gov,对187项成人手术患者术后神经认知障碍或延迟神经认知恢复预防的随机对照试验进行多变量元回归分析,发现试验来源地区、对照组发生率、麻醉药物、注册状态、样本量分析及偏倚风险等试验特征与预防效果显著相关,其中右美托咪定研究最多但证据确定性极低。
要点
- 试验来源地区与预防效果相关,中国以外地区效果较低
- 对照组发生率越高,预防效果越明显
- 注册试验效果较好,但样本量分析及高偏倚风险与效果降低相关
核心结论
- 试验特征显著影响术后神经认知障碍或延迟神经认知恢复预防效果的研究结果。
- 识别并解决地区差异原因可提升未来试验质量与全球一致性。
研究设计与样本
- 系统综述与随机对照试验的多变量元回归分析,共纳入187项试验。
- 检索Ovid MEDLINE、EMBASE、Web of Science和ClinicalTrials.gov,方案注册于PROSPERO(CRD42024543584)。
主要发现
- 与来自中国的试验相比,美国/加拿大(比值比之比3.04;95%CI 1.62-5.73;P=0.001)、欧洲/澳大利亚/新西兰(1.58;1.04-2.40;P=0.033)及其他地区(2.0;1.19-3.36;P=0.009)的试验效果降低。
- 对照组术后神经认知障碍或延迟神经认知恢复发生率较高与效果更好相关(0.98;0.97-0.99;P<0.001)。
- 涉及挥发性麻醉药的试验效果低于右美托咪定(2.12;1.16-3.86;P=0.014),腹部手术相关试验效果亦较低。
- 注册试验效果较好(0.69;0.50-0.95;P=0.022),而进行样本量分析的试验效果降低(1.43;1.06-1.94;P=0.021)。
- 报告结果选择高偏倚风险的试验效果降低(2.99;1.04-8.59;P=0.041),右美托咪定研究最多但证据确定性极低。
临床怎么用
- 解读术后神经认知障碍预防试验结果时需考虑试验来源地区、麻醉药物及方法学质量等特征。
- 右美托咪定可能具有潜在益处,但当前证据确定性极低,临床决策需谨慎。
局限性
- 证据确定性极低,尤其关于右美托咪定的潜在益处。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative neurocognitive disorder and delayed neurocognitive recovery (pNCD/dNCR) are common yet unresolved complications after surgery. METHODS: We conducted a systematic literature search in resources of Ovid MEDLINE, EMBASE, Web of Science, and ClinicalTrials.gov and multivariable meta-regression analyses of RCTs to identify trial-level characteristics associated with prevention effectiveness in pNCD/dNCR research. Trials investigating pNCD/dNCR prevention in adult surgical patients were eligible. Trials performed in paediatric patients or assessing cognitive changes on the same day of surgery were excluded. Effectiveness associated with trial-level characteristics was assessed using ratio of odds ratio (OR) and 95% confidence interval (CI). RESULTS: We analysed 187 eligible trials. Trials originating from the USA/Canada (ratio of OR, 3.04; 95% CI, 1.62-5.73; P=0.001), Europe/Australia/New Zealand (1.58; 1.04-2.40; P=0.033), and other regions (2.0; 1.19-3.36; P=0.009) were associated with reduced effectiveness compared with trials from China. Higher pNCD/dNCR incidence in control groups was associated with greater effectiveness (0.98; 0.97-0.99; P<0.001). Trials involving volatile anaesthetics (2.12; 1.16-3.86; P=0.014) were associated with reduced effectiveness compared with dexmedetomidine and abdominal surgery, respectively. Registered trials exhibited enhanced effectiveness (0.69; 0.50-0.95; P=0.022), whereas those with power analyses reported reduced effectiveness (1.43; 1.06-1.94; P=0.021). Trials with a high risk of bias in the selection of the reported result were associated with reduced effectiveness (2.99; 1.04-8.59; P=0.041). Dexmedetomidine was the most studied intervention, showing potential benefits, though evidence certainty was very low. CONCLUSIONS: Trial-level characteristics were significantly associated with prevention effectiveness in pNCD/dNCR research. Identifying and addressing the underlying causes of regional differences might enhance the quality and consistency of future trials on a global level. SYSTEMATIC REVIEW PROTOCOL: PROSPERO (CRD42024543584).
引用
- Lahiri NK, Vuckovic N, Sidhu AS, et al. Patterns of prevention effectiveness in postoperative neurocognitive disorder and delayed neurocognitive recovery research: a systematic review with meta-regression of randomised trials. Br J Anaesth. 2025. PMID: 40480916. doi:10.1016/j.bja.2025.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。